When YAP1 activity was inhibited using verteporfin the growth of MLS cells both in vitro and in vivo was impaired, thereby making overactive YAP1 as a potential therapeutic target in MLS [50]. This evidence concerns the gene YAP1 and McLeod neuroacanthocytosis syndrome.